Author: BAMBUSA THERAPEUTICS,Inc

Posted Date:

April 30, 2026

Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis

BAMBUSA THERAPEUTICS,Inc

April 30, 2026
Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

BAMBUSA THERAPEUTICS,Inc

April 1, 2026
Bambusa Therapeutics Appoints Todd James Chief Financial Officer

BAMBUSA THERAPEUTICS,Inc

March 19, 2026